Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study

BACKGROUND. Immune-checkpoint-inhibitors (ICIs) have dramatically improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations. However, ICIs can also cause severe or even fatal immune-mediated adverse-events (irAE). Here, we ident...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Salem, Joe-Elie, Manouchehri, Ali, Moey, Melissa, Lebrun-Vignes, Bénédicte, Bastarache, Lisa, Pariente, Antoine, Gobert, Aurélien, Spano, Jean-Philippe, Balko, Justin M., Bonaca, Marc P., Roden, Dan M., Johnson, Douglas B., Moslehi, Javid J.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287923/
https://ncbi.nlm.nih.gov/pubmed/30442497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30608-9
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki